Nutriband (NASDAQ:NTRB) Stock Price Up 2.3% – Here’s What Happened

Posted by Joseph Griffin on May 21st, 2026

Nutriband Inc. (NASDAQ:NTRB – Get Free Report) shares shot up 2.3% during trading on Wednesday . The stock traded as high as $3.59 and last traded at $3.53. 7,163 shares were traded during mid-day trading, a decline of 24% from the average session volume of 9,477 shares. The stock had previously closed at $3.45.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nutriband in a report on Friday, May 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Read Our Latest Analysis on NTRB

Nutriband Stock Up 2.3%

The company has a quick ratio of 6.21, a current ratio of 6.36 and a debt-to-equity ratio of 0.01. The company has a market cap of $42.91 million, a P/E ratio of -1.36 and a beta of 1.96. The company has a fifty day moving average of $3.83 and a 200 day moving average of $4.42.

Institutional Trading of Nutriband

A hedge fund recently bought a new stake in Nutriband stock. Cogent Private Wealth Inc. purchased a new stake in shares of Nutriband Inc. (NASDAQ:NTRB – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 16,014 shares of the company’s stock, valued at approximately $73,000. Cogent Private Wealth Inc. owned 0.13% of Nutriband as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 19.70% of the company’s stock.

About Nutriband

(Get Free Report)

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.